FIELD: biotechnology.
SUBSTANCE: invention relates to a binding molecule specific to a disease-related antigen and CD3, as well as to a composition containing it.
EFFECT: invention is effective for the treatment of a disease associated with B7-H3, CEACAM5/CEACAM6, EGRF, EphA2, gpA33, HER2/neu, VEGF, 5T4, IL13Rα2 or CD19.
21 cl, 36 dwg, 20 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES | 2019 |
|
RU2824391C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| ANTIBODIES AGAINST GUCY2c AND THEIR USE | 2019 |
|
RU2812113C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
